Candel Therapeutics (CADL) Other Non-Current Liabilities (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Other Non-Current Liabilities data on file, last reported at $15.6 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $15.6 million; the trailing twelve-month figure through Dec 2025 stood at $15.6 million (changed N/A YoY), and the FY2025 full-year result was $15.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities retreated to $15.6 million in Q4 2025, from $15.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $27.4 million in Q3 2021 to a low of $433000.0 in Q3 2023.
• A 5-year average of $9.1 million and a median of $5.0 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities plunged 90.64% in 2023 and jumped 3568.82% in 2024, its largest moves.
• Tracing CADL's Other Non-Current Liabilities over 5 years: stood at $18.3 million in 2021, then sank by 89.69% to $1.9 million in 2022, then slumped by 51.33% to $916000.0 in 2023, then jumped by 1634.28% to $15.9 million in 2024, then retreated by 1.81% to $15.6 million in 2025.
• Business Quant data shows CADL's Other Non-Current Liabilities at $15.6 million in Q4 2025, $15.9 million in Q3 2024, and $14.2 million in Q2 2024.